NMT Medical, Inc (NMTI) Terminates Further Enrollment in MIST II
1/23/2008 9:07:38 AM
BOSTON--(BUSINESS WIRE)--NMT Medical, Inc. (NASDAQ: NMTI) today announced that the Company is closing down its patent foramen ovale (PFO)/migraine trial, MIST II, to focus its resources on its PFO/stroke opportunity. The move is expected to save the Company approximately $14 million over the next two to three years as it redistributes investments originally budgeted for MIST II. As a result of this decision, NMT has ceased patient enrollment in MIST II, which was being conducted at 20 centers in the United States.
comments powered by